These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 9426869)

  • 1. PET and SPECT studies in Parkinson's disease.
    Brooks DJ
    Baillieres Clin Neurol; 1997 Apr; 6(1):69-87. PubMed ID: 9426869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Motor disturbance and brain functional imaging in Parkinson's disease.
    Brooks DJ
    Eur Neurol; 1997; 38 Suppl 2():26-32. PubMed ID: 9387800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease.
    Thobois S; Guillouet S; Broussolle E
    Neurophysiol Clin; 2001 Oct; 31(5):321-40. PubMed ID: 11817273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences.
    Thobois S; Jahanshahi M; Pinto S; Frackowiak R; Limousin-Dowsey P
    Neuroimage; 2004 Sep; 23(1):1-16. PubMed ID: 15325346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET studies of the striatal dopaminergic system in Parkinson's disease (PD).
    Piccini P; Turjanski N; Brooks DJ
    J Neural Transm Suppl; 1995; 45():123-31. PubMed ID: 8748617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Functional neuroimaging in movement disorders].
    Borbély K
    Orv Hetil; 2001 Oct; 142(43):2347-55. PubMed ID: 11760452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of PET in Parkinson's disease.
    Shinotoh H; Calne DB
    Brain Cogn; 1995 Aug; 28(3):297-310. PubMed ID: 8546856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [SPECT and PET in Parkinson's disease].
    Matsuda H
    Nihon Rinsho; 2000 Oct; 58(10):2000-6. PubMed ID: 11068438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography studies in parkinsonism.
    Eidelberg D
    Neurol Clin; 1992 May; 10(2):421-33. PubMed ID: 1584183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications.
    Kuriakose R; Stoessl AJ
    Prog Brain Res; 2010; 184():177-92. PubMed ID: 20887875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease.
    de Natale ER; Niccolini F; Wilson H; Politis M
    Int Rev Neurobiol; 2018; 141():131-172. PubMed ID: 30314595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET measurements of dopaminergic pathways in the brain.
    Perlmutter JS; Moerlein SM
    Q J Nucl Med; 1999 Jun; 43(2):140-54. PubMed ID: 10429509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease.
    Kordower JH; Freeman TB; Snow BJ; Vingerhoets FJ; Mufson EJ; Sanberg PR; Hauser RA; Smith DA; Nauert GM; Perl DP
    N Engl J Med; 1995 Apr; 332(17):1118-24. PubMed ID: 7700284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PET and SPECT in Parkinson's disease].
    Blesa R
    Rev Neurol; 1997 Aug; 25 Suppl 2():S147-50. PubMed ID: 9280681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurodegenerative movement disorders: the contribution of functional imaging.
    Piccini P
    Curr Opin Neurol; 2004 Aug; 17(4):459-66. PubMed ID: 15247543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging end points for monitoring neuroprotection in Parkinson's disease.
    Brooks DJ
    Ann Neurol; 2003; 53 Suppl 3():S110-8; discussion S118-9. PubMed ID: 12666103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
    Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB
    Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Presynaptic nigrostriatal function in Parkinson disease and Parkinson-plus syndromes. Comparative studies using positron emission tomography with L-6-(18F)fluorodopa].
    Cordes M; Poewe W
    Nervenarzt; 1994 Oct; 65(10):696-9. PubMed ID: 7808568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional imaging studies of dopamine system and cognition in normal aging and Parkinson's disease.
    Kaasinen V; Rinne JO
    Neurosci Biobehav Rev; 2002 Nov; 26(7):785-93. PubMed ID: 12470690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relief of akinesia by apomorphine and cerebral metabolic changes in Parkinson's disease.
    Broussolle E; Cinotti L; Pollak P; Landais P; Le Bars D; Galy G; Lavenne F; Khalfallah Y; Chazot G; Mauguière F
    Mov Disord; 1993 Oct; 8(4):459-62. PubMed ID: 8232355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.